Factors influencing trough and 90-minute plasma dabigatran etexilate concentrations among patients with non-valvular atrial fibrillation

Dabigatran etexilate, a direct oral anti-coagulation agent, is used in the prevention of thromboembolism in patients with non-valvular atrial fibrillation (NVAF). However, for reasons that are not fully understood, plasma dabigatran etexilate concentrations (PDC) vary significantly among patients. W...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Thrombosis research 2016-09, Vol.145, p.100-106
Hauptverfasser:	Tomita, Hideharu, Araki, Takuya, Kadokami, Toshiaki, Yamada, Satoshi, Nakamura, Ryo, Imamura, Yoshihiro, Fukuyama, Takaya, Nagano, Daisuke, Hashimoto, Tomoya, Uematsu, Akiko, Hosokawa, Kazuya, Yamamoto, Koujirou, Ueda, Shin-ichiro, Ando, Shin-ichi
Format:	Artikel
Sprache:	eng
Schlagworte:	Activated partial prothrombin time Antithrombins - administration & dosage Antithrombins - therapeutic use Atrial Fibrillation - blood Atrial Fibrillation - drug therapy D-dimer Dabigatran Dabigatran - administration & dosage Dabigatran - therapeutic use Female Humans Male Plasma dabigatran concentration Risk Factors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!